文献速递结核与非结核分枝杆菌

无症状结核病全疾病谱:流行病学、诊断与公共卫生意义范围综述

Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该范围综述按PRISMA-ScR指南汇总流行病学研究、患病率调查、建模分析和WHO指南,发现细菌学确诊结核中至多30%-50%可无症状,其中相当比例涂片阳性,20%-30%在2年内进展为有症状结核,现有症状筛查漏诊多,需将无症状阶段纳入结核控制框架。

要点

  • 细菌学确诊结核中至多30%-50%诊断时无症状,症状筛查漏诊多。
  • 无症状者中相当比例涂片阳性,可能参与社区传播。
  • 20%-30%无症状者在2年内进展为有症状结核。

核心结论

  • 无症状结核是结核病疾病谱中隐匿但有后果的组成部分,将其纳入控制框架对准确估计负担、及时治疗和实现消除目标至关重要。

研究设计与样本

  • 按PRISMA-ScR指南开展的范围综述,纳入流行病学研究、患病率调查、建模分析和近期WHO指南,聚焦定义、诊断、传播潜力、自然史和公共卫生意义。

主要发现

  • 患病率调查显示细菌学确诊结核病例中至多30%-50%在诊断时无症状,其中许多在症状筛查下未被发现。
  • 无症状者中相当比例涂片阳性,提示其潜在社区传播作用。
  • 影像学和分子研究显示无症状者存在持续肺部病理和免疫激活,20%-30%在2年内进展为有症状疾病。

关键数值与推荐

  • 细菌学确诊结核中至多30%-50%可无症状。
  • 无症状结核中20%-30%在2年内进展为有症状疾病。
  • 诊断挑战包括低菌负荷和无法咳痰,计算机辅助影像、痰液合并和宿主转录组生物标志物等创新正在推进检测。

临床怎么用

  • 应认识无症状结核阶段,将其整合入结核控制框架以准确估计负担和及时治疗。
  • 未来需聚焦可扩展诊断、生物标志物验证和针对脆弱人群的公平筛查策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis (TB) remains a leading infectious cause of death globally. While control strategies have traditionally prioritized symptomatic cases, growing evidence highlights the substantial burden of asymptomatic or subclinical TB, microbiologically confirmed disease without classical symptoms, posing challenges for detection, treatment, and elimination efforts. METHODS: We conducted a scoping review in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. We selected epidemiological studies, prevalence surveys, modeling analyses, and recent World Health Organization (WHO) guidance to summarize the current understanding of asymptomatic TB. We examined definitions, diagnostic approaches, transmission potential, natural history, and public health implications, with special focus on vulnerable populations. RESULTS: Prevalence surveys reveal that up to 30%-50% of bacteriologically confirmed TB cases may be asymptomatic at diagnosis, many of whom remain undetected under symptom-based screening. A substantial fraction of these individuals is smear positive, underscoring their potential role in community transmission. Despite clinical silence, radiographic and molecular studies demonstrate ongoing lung pathology and immune activation, with 20%-30% progressing to symptomatic disease within 2 years. Diagnostic challenges include low bacillary burden and inability to expectorate sputum, though innovations, such as computer-aided radiography, sputum pooling, and host transcriptomic biomarkers, are advancing detection. CONCLUSIONS: Asymptomatic TB represents a hidden but consequential component of the TB disease spectrum. Recognition and integration of this stage into TB control frameworks are essential for accurate burden estimation, timely treatment, and achievement of elimination targets. Future efforts must focus on scalable diagnostics, biomarker validation, and equitable screening strategies tailored to vulnerable populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Duarte BB, Ellner J, Wright AD, et al. Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications. Clin Infect Dis. 2026. PMID: 41974031. doi:10.1093/cid/ciag150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。